Pesquisa de Pacientes
Entrar
Todos os estudos
RecrutamentoConfirmatório terapêutico (Fase III)Intervencionista

A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec when Switching from Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults with Type 2 Diabetes

Researchers are conducting a study to see if a new insulin that's taken once a week, called insulin icodec, is a good option for adults with type 2 diabetes. This new insulin is being compared to a common daily insulin treatment, Lantus. The main goal is to find out if the once-a-week insulin can control blood sugar as effectively as the daily one. The study will also look at how safe the new insulin is, how happy people are with their treatment, and how it affects their blood sugar levels throughout the day. This is an important step in developing new, potentially more convenient treatments for type 2 diabetes.

Em resumo

Status
Recrutamento
Fase
Confirmatório terapêutico (Fase III)
Patrocinador
Novo Nordisk A/S
Meta de inscrição
145
Iniciar
26 Mar 2024
Diabetes Tipo 2

Sobre o que é este estudo?

This study is all about finding a new way to manage type 2 diabetes. Many people with type 2 diabetes need to take insulin injections every day to keep their blood sugar levels healthy. This study is testing a new type of insulin that only needs to be taken once a week. It's called insulin icodec.

The researchers want to see if this new once-a-week insulin works as well as, or even better than, the daily insulin that many people currently use, such as Lantus. They'll be carefully checking blood sugar levels to see if the new insulin helps to keep them stable. They'll also be looking at how safe the new insulin is and if it causes any unwanted side effects, especially very low blood sugar.

Ultimately, this study aims to find out if a weekly insulin injection could be a convenient and effective option for people with type 2 diabetes, potentially making it easier to manage their condition.

Pontos principais

  • This study is testing a new once-a-week insulin for type 2 diabetes.
  • It aims to see if it's safe and as effective as daily insulin.
  • Blood sugar control and treatment satisfaction are key measures.
  • Participants will be adults with type 2 diabetes currently on daily insulin.

Quem pode ser elegível?

This study is looking for adult volunteers of any gender who have type 2 diabetes. You need to be 18 years old or older to take part.

Currently, you should be taking daily long-acting (basal) insulin to manage your type 2 diabetes. This study will involve switching from your current daily insulin to either the new weekly insulin or another daily insulin for comparison.

There might be other specific health requirements or conditions that would make someone unsuitable for the study, but these would be discussed in detail with the study team.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem 18 anos ou mais?
  2. Do you have type 2 diabetes?
  3. Are you currently taking a daily long-acting insulin?
  4. Are you able to attend regular study visits?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you join this study, your participation will involve several visits to the study clinic over a period of about 6 months, plus some follow-up. You will be randomly assigned to receive either the new once-a-week insulin (insulin icodec) or a standard daily insulin (Lantus).

Throughout the study, you'll have regular check-ups, blood tests, and assessments of your blood sugar levels. You'll also be asked to keep track of your blood sugar at home and fill out questionnaires about how you feel about your treatment. The study team will provide all the medication and instructions you need.

Riscos e benefícios potenciais

Taking part in a study like this could offer potential benefits, such as receiving new treatments or close medical monitoring. However, there are also potential risks, including side effects from the medications, like low blood sugar (hypoglycaemia), or the possibility that the new treatment might not work as well for you. Your safety will be closely monitored by the study team. Remember, deciding whether or not to join is completely up to you, and you can withdraw from the study at any time without giving a reason.

Localizações (4)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Polônia
  • —
    Não verificado
    Espanha
  • —
    Não verificado
    Bulgária
  • —
    Não verificado
    Alemanha

Perguntas frequentes

What is the new insulin being tested?

It's called insulin icodec, and it's designed to be taken once a week.

Qual é o principal objetivo deste estudo?

To see if the once-a-week insulin is safe and works as well as daily insulin for controlling blood sugar in type 2 diabetes.

What does HbA1c mean?

HbA1c is a blood test that shows your average blood sugar levels over the past 2-3 months.

Saberei qual tratamento estou recebendo?

No, you will be randomly assigned to one of the treatments, and neither you nor the study team will know which one you are receiving.

Quanto tempo durará o estudo?

The main part of the study where your blood sugar is checked will last for about 6 months, with some follow-up beyond that.

Como saber mais

Registro oficial do julgamento

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Study to Evaluate the Efficacy and Safety of Once-weekly I…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.